BIO CEO Conference Live Blog: Day 2

Editor's note: The person posting comments as "RJ Kirk" in Tuesday's BIO CEO Live Blog is not the chairman of Clinical Data.

NEW YORK (TheStreet) -- Small- and midsized biotech companies get a second day in the investor spotlight this week at the 13th annual BIO CEO & Investor Conference.

I'll be continuing my live-blogging from the BIO CEO conference today, presenting news updates and analysis live from the presentation rooms and breakout (Q&A) sessions.

Biotech companies on my coverage list Tuesday include: Spherix (SPEX), SuperGen (SUPG), Clinical Data (CLDA), Cel-Sci (CVM), Aastrom Biosciences (ASTM), AVI BioPharma (AVII) and Neoprobe (NEOP).

>>BIO CEO Conference Blog, Day 1

I'll also be reporting on presentations from StemCells (STEM), YM BioSciences (YMI), Ziopharm Oncology (ZIOP), Cell Therapeutics (CTIC), Icagen (ICGN) and Telik (TELK).

The BIO CEO conference is sponsored by BIO, the biotech industry-lobbying group based in Washington, D.C., and typically invites small- and mid-cap biotech companies to present to an audience of institutional investors. Smaller biotech companies, in particular, lack extensive research coverage from investment banks, so this conference is a good way for these companies to get their stories in front of investors.

This BIO CEO confab live blog will be similar to the real-time coverage I provided in January of the J.P. Morgan Healthcare Conference. Expect breaks in between my postings today because I'll be moving around the conference and waiting for companies to present throughout the day.

I'll do my best to give you continuous coverage, but understand that I'm somewhat at the mercy of the AT&T network and my ability to type into my iPhone while weaving through crowds and listening to biotech executives speak.

Your best bet is to check back into the live blog several times throughout the day.

Like my previous live blogs, I want to keep today's coverage interactive, so feel free to ping me with comments and questions. I will publish and respond to as many of your comments and questions as I can.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: [e-mail].

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.